Clinical-stage immuno-oncology company Affimed N.V. (Nasdaq:AFMD) reported on Wednesday that the first patient has been dosed in the first-in-human clinical trial of the innate cell engager (ICE) AFM28.
The phase 1 multicentre, open label, dose escalation study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of AFM28 monotherapy in patients with CD123-positive (r/r) acute myeloid leukaemia (AML).
AFM28 directs natural killer (NK) cells to CD123-positive leukaemic cells, including blasts and leukaemic stem and progenitor cells, inducing their depletion in samples of patients with AML and myelodysplastic syndrome (MDS).
Affimed also intends to develop AFM28 in combination with allogeneic NK cell therapy.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA